ReviewActa pharmaceutica Sinica. B2025
Modified probiotics and the related combinatorial therapeutics.
Review in Acta pharmaceutica Sinica. B, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Engineered probiotics couple photothermal cuproptosis with biomechanical disruption and immune activation.Bioactive materials · 2027Article
- An Intravesical Akkermansia muciniphila-Based Chemo-Immunotherapeutic Platform for Bladder Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
- Multiscale rational construction strategy for polyphenol self-assembled delivery systems: from nanoscale to microscale.Materials today. Bio · 2026Review
- Development of bacterial sonosensitizer hybrid systems to enhance cancer sono-immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- An oral immune enhancer with excellent biocompatibility for effectively strengthening body's immunity and treating cancer.Acta pharmaceutica Sinica. B · 2026Article
- Probiotic-drug co-delivery system enhances sulfasalazine activation for inflammatory bowel disease therapy.Materials today. Bio · 2026Article
- Advances in the engineering of living probiotics for cancer immunotherapy.Theranostics · 2026Review
- Probiotic Carriers for Tumor-Targeted Therapy: Applications and Challenges.International journal of nanomedicine · 2026Review
- The challenges and strategies for navigatingTheranostics · 2026Review
- Engineered probiotics for inflammatory bowel disease therapy: mechanisms, delivery strategies, and precision medicine.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics have shown excellent application prospects in preventing and treating many diseases. However, their sensitivity to the harsh environment
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.